NewAmsterdam Pharma Co N.V. Income Statement
NAMS / Health Care|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
NewAmsterdam Pharma Co N.V. reported $23M in revenue and $204M in net loss for FY2025. Revenue has declined at a 39.7% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M | - |
| SG&A Expense | $106.4M | $70.4M | $37.6M | $19.5M | $6.0M |
| R&D Expense | $141.8M | $151.4M | $159.4M | $86.7M | $29.0M |
| Operating Income | -$225.7M | -$176.3M | -$183.0M | -$3.6M | -$35.0M |
| Interest Expense | - | - | - | $287.0K | $411.0K |
| Income Tax | - | -$1.0K | $27.0K | - | - |
| Net Income | -$203.8M | -$241.6M | -$176.9M | -$22.6M | -$41.8M |
| EPS (Basic) | -$1.72 | -$2.56 | -$2.15 | -$1.19 | -$3.81 |
| EPS (Diluted) | -$1.72 | -$2.56 | -$2.15 | -$1.19 | -$3.81 |
| Shares Outstanding | 118.4M | 94.4M | 82.2M | 19.0M | 11.0M |
| Operating Margin | - | - | - | -3.5% | - |
| Profit Margin | - | - | - | -22.0% | - |